We came across a bullish thesis on Nutex Health Inc. on Buffetts Disciple’s Substack by Aled. In this article, we will summarize the bulls’ thesis on NUTX. Nutex Health Inc.'s share was trading at $149.80 as of January 28th. NUTX’s trailing P/E was 7.28 according to Yahoo Finance. Nutex Health Inc. ($NUTX) is a healthcare operator specializing in microhospitals—small, highly focused facilities providing urgent care, imaging, and surgical services 24/7. This model allows Nutex to treat roughly 95% of pati ...

Group 1: Palvella Therapeutics Inc. (PVLA) - Palvella is a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases with no FDA-approved treatments [2] - Its lead product, QTORIN rapamycin, targets microcystic lymphatic malformations and has a multi-billion-dollar market opportunity if approved [2] - The stock rose from $25 on March 10, 2025, to a 52-week high of $114.69 on December 22, 2025, before pulling back to $99.88 [3] Group 2: Cidara Therapeutics Inc. (CDTX) - Cidara is developing a preventive therapy for influenza and has agreed to be acquired by Merck for $221.50 per share, totaling approximately $9.2 billion [4] - The stock was trading at $18.98 when profiled on November 21, 2024 [4] Group 3: Celcuity Inc. (CELC) - Celcuity is focused on targeted therapies for oncology, with its lead drug candidate Gedatolisib aimed at breast and prostate cancers [5] - The stock increased from $12.60 on December 4, 2024, to an all-time high of $112.64 on December 12, 2025, before retreating to $99.16 [6] Group 4: Nanobiotix (NBTX) - Nanobiotix is a late-stage clinical biotechnology company developing physics-based therapies for cancer [7] - Its lead candidate, NBTXR3, is undergoing a phase III study for head and neck squamous cell carcinoma, with interim data expected in the first half of 2027 [8] - The stock rose from $12.23 on September 19, 2025, to a high of $30.35 on October 13, 2025, before trading around $21 [10] Group 5: Terns Pharmaceuticals Inc. (TERN) - Terns Pharma is developing small-molecule candidates for serious diseases, with TERN-701 targeting chronic myeloid leukemia [12] - Recent data showed a 75% major molecular response rate among patients receiving higher doses [13] - The stock increased from $5.98 on August 6, 2025, to an all-time high of $48.26 on December 10, 2025, before pulling back to around $40 [14] Group 6: DBV Technologies S.A. (DBVT) - DBV Technologies is developing an epicutaneous immunotherapy for food allergies, with its lead product, the VIASKIN Peanut patch, showing positive results in a phase 3 study [15] - The company aims to submit a Biologics License Application in the first half of 2026, with potential sales of $1.5 billion by 2030 if approved [15] - The stock rose from $10.64 on October 2, 2025, to a high of $26.18 on December 17, 2025, before trading around $19 [16] Group 7: Nutex Health Inc. (NUTX) - Nutex Health reported a significant turnaround from a $424 million net loss in 2022 to a $59 million net income for the nine months ended September 30, 2025 [17] - Revenue increased from $219 million in 2022 to $723.6 million in the first nine months of 2025 [17] - The stock rose from $33.56 on November 25, 2024, to a 52-week high of $193.07 before closing at $182.23 [18] Group 8: Inhibrx Biosciences Inc. (INBX) - Inhibrx is developing biologic therapies for cancer, with Ozekibart showing significant improvement in progression-free survival in chondrosarcoma [19] - The company plans to submit a biologics license application for Ozekibart in the second quarter of 2026 [20] - The stock rose from $18.35 on July 8, 2025, to an all-time high of $94.57 on December 22, 2025, before trading around $77 [21] Group 9: GRAIL Inc. (GRAL) - GRAIL focuses on early cancer detection with its Galleri test, which is not yet FDA-approved [23] - The company expects to submit a PMA for the Galleri test in Q1 2026 [23] - The stock increased from $48.50 on September 26, 2025, to a high of $115.76 on November 25, 2025, before trading around $88 [24] Group 10: Cogent Biosciences Inc. (COGT) - Cogent is developing precision therapies for genetically defined diseases, with Bezuclastinib being its lead candidate [25] - The company submitted its first NDA to the FDA for Non-AdvSM, with additional submissions planned for GIST and advanced systemic mastocytosis [26] - The stock rose from $7.25 on July 2, 2025, to a 52-week high of $43.73 on December 8, 2025, before easing back to around $35 [26] Group 11: Sol-Gel Technologies Ltd. (SLGL) - Sol-Gel has two FDA-approved products for dermatological conditions and is developing investigational products [27] - A phase III trial for SGT-610 is ongoing, with results expected in Q4 2026 [28] - The stock rose from $7.26 on May 7, 2025, to a high of $52.26 on October 6, 2025, before trading around $43 [28] Group 12: Zenas BioPharma Inc. (ZBIO) - Zenas is focused on therapies for autoimmune diseases, with Obexelimab in phase 3 trials for IgG4-RD [29] - Positive data from a phase 2 trial in multiple sclerosis showed a 95% reduction in new lesions [30] - The stock rose from $8.79 on December 17, 2024, to a high of $44.60 on December 24, 2025, before pulling back to around $35 [31]

Group 1: Market Overview - U.S. stocks experienced an upward trend, with the Dow Jones increasing by over 250 points on Thursday [1] Group 2: Notable Company Performances - Nutex Health Inc reported quarterly sales of $267.804 million, surpassing market estimates of $213.812 million, leading to a 37.3% increase in share price to $154.14 [1] - PACS Group, Inc. shares rose by 50.9% to $25.46 following better-than-expected quarterly sales results [3] - Cerence Inc's shares jumped 37.3% to $10.88 after announcing better-than-expected fourth-quarter financial results, with Goldman Sachs maintaining a Neutral rating and raising the price target from $10 to $11 [3] - New Fortress Energy Inc saw a 20.7% increase in share price to $1.40 [3] - Aduro Clean Technologies Inc gained 18.5% to $11.72 after a major global firm completed pilot-scale steam-cracking trials using its technology [3] - Exact Sciences Corp's shares increased by 17.6% to $101.34 after Abbott agreed to acquire the company for $105 per share, valuing the deal at approximately $20 billion [3] - Olema Pharmaceuticals Inc rose 17.3% to $22.78 [3] - Design Therapeutics Inc gained 13.9% to $8.36, with RBC Capital upgrading the stock from Sector Perform to Outperform and raising the price target from $6 to $13 [3] - Terawulf Inc's shares increased by 11.5% to $13.64 [3] - Cipher Mining Inc rose 10.6% to $16.17 after announcing a 10-year deal with Fluidstack for an additional 39 megawatts of critical IT load [3] - IREN Ltd's shares increased by 10.2% to $50.50 [3] - JOYY Inc gained 7.6% to $64.52 after reporting better-than-expected third-quarter financial results and issuing fourth-quarter sales guidance above estimates [3] - Walmart Inc's shares rose 6.5% to $107.17 after reporting third-quarter financial results and raising FY26 revenue and adjusted EPS outlook, along with a transfer of its listing from NYSE to Nasdaq effective Dec. 9 [3] - Guardant Health Inc surged 8.8% to $108.37 [3]

Core Insights - Several stocks experienced significant movements in after-hours trading, influenced by earnings announcements and financing updates, particularly in the healthcare and biotech sectors [1] Company Summaries - **PACS Group Inc. (PACS)**: The stock surged 45.48% to $24.48 after a 16.63% increase during regular trading, closing at $16.83. The company reported Q3 net income of $52.4 million ($0.32 per share), up from $15.6 million ($0.10 per share) a year ago. Revenue increased to $1.345 billion from $1.026 billion. For fiscal 2025, PACS expects revenue between $5.25 billion and $5.35 billion, with adjusted EBITDA projected at $480 million to $490 million [2] - **Zynex, Inc. (ZYXI)**: The stock rose 4.49% after hours to $0.58, following a 32.14% gain during regular trading. The company reported a net loss of $42.9 million ($1.42 per share) for the quarter ended September 30, 2025, compared to a net income of $2.3 million ($0.07 per share) in the same period last year. Net revenue fell to $13.4 million from $50.0 million [3] - **Genenta Science S.p.A. (GNTA)**: The stock increased 7.34% after hours to $1.90, recovering from an 11.06% decline to $1.77. Last month, the company announced a securities purchase agreement for 4,285,715 American Depositary Shares at $3.50 per ADS, raising approximately $15.0 million before fees and expenses [4] - **Ekso Bionics Holdings, Inc. (EKSO)**: The stock gained 4.22% in after-hours trading to $4.20, after closing at $4.03, down 3.47% earlier in the day. In late October, the company disclosed a registered direct offering of 769,490 shares priced at $4.81 per share [5] - **Nutex Health Inc. (NUTX)**: The stock advanced 9.64% after hours to $123.00, following a 13.09% rise during regular trading to $112.19. The company reported Q3 net income of $55.4 million, reversing a net loss of $8.8 million in the same period last year. Revenue climbed to $267.8 million, up from $78.8 million, marking a 239.9% increase [6]

Core Insights - Nutex Health Inc. reported a significant financial performance for the three and nine months ended September 30, 2025, with a revenue growth of 225% and a record cash balance of $166 million [5][7]. Financial Highlights for Three Months Ended September 30, 2025 - Total revenue reached $267.8 million, a 239.9% increase from $78.8 million in the same period of 2024 [7]. - Hospital division revenue was $260.2 million, up 262.8% from $71.7 million in Q3 2024 [7]. - Net income attributable to Nutex Health was $55.4 million, compared to a net loss of $8.8 million in Q3 2024 [7]. - EBITDA for the quarter was $91.8 million, a 2014% increase from $4.3 million in Q3 2024 [7]. - Adjusted EBITDA was $98.5 million, compared to $9.7 million in Q3 2024 [7]. - Operating income improved to $130.4 million from $9.7 million in the same quarter of 2024 [7]. Financial Highlights for Nine Months Ended September 30, 2025 - Total revenue for the nine months was $723.6 million, a 225.5% increase from $222.3 million in the same period of 2024 [7]. - Net income attributable to Nutex Health was $59.0 million, compared to a net loss of $9.5 million in the first nine months of 2024 [7]. - EBITDA for the nine months was $142.9 million, a 616.4% increase from $19.9 million in the same period of 2024 [7]. - Adjusted EBITDA reached $243.0 million, compared to $16.1 million in the first nine months of 2024 [7]. - Total visits at the Hospital Division increased to 140,074, up 13.9% from 122,944 in the same period of 2024 [7]. Operational Insights - The company has a strong pipeline for future growth, reflecting continued demand for small hospitals across the country [6]. - Approximately 70% of hospital revenue was attributed to higher acuity claims and success through the Independent Dispute Resolution (IDR) process [7]. - The company has maintained a high collection rate of over 80% on legal determinations won through arbitration [7]. Compliance and Governance - Nutex Health has regained compliance with Nasdaq Listing Rule 5250(c)(1) following the timely filing of its Form 10-Q for the period ended June 30, 2025 [9][10].

Core Insights - Several small-cap biotech and pharma companies experienced notable gains in after-hours trading, with Nutex Health being the most significant mover following its quarterly results [1] Company Summaries - **Nutex Health Inc. (NUTX)**: The company saw its stock surge by 20.97% to $120.00 after reporting a third-quarter net loss of $17.7 million, compared to a net loss of $0.4 million in the same period last year. However, total revenue increased significantly by 220.7% year-over-year to $244.0 million from $76.1 million [2] - **Bullfrog AI Holdings, Inc. (BFRG)**: The stock rose by 5.87% to $0.9798 in after-hours trading, likely due to investor positioning ahead of an upcoming technical presentation at the AI Drug Discovery & Development Summit 2025 [3] - **Clearside Biomedical, Inc. (CLSD)**: The company’s stock increased by 6.51% to $3.27 after reporting a narrower third-quarter net loss of $5.97 million compared to $7.69 million last year, although revenue fell sharply to $201 thousand from $1.04 million [4] - **Aytu BioPharma, Inc. (AYTU)**: The stock climbed 8.91% to $2.20, following a prior close of $2.02. The company reported a first-quarter net income of $2.0 million versus $1.5 million a year ago, with revenue of $13.9 million compared to $16.6 million in the prior year [5] - **Adicet Bio, Inc. (ACET)**: The stock added 5.21% to $0.6325, with a reported third-quarter net loss of $12.4 million, slightly wider than last year's $11.6 million. Revenue declined by 16% year-over-year to $6.8 million, but the company reiterated its 2025 revenue guidance [6] - **OKYO Pharma Limited (OKYO)**: The stock rose by 2.44% to $2.18. The CEO is scheduled to present at the Ophthalmology Innovation Summit XV, discussing the investigational drug candidate urcosimod, which has shown promising results in Phase 2 trials [7]

Core Viewpoint - Nutex Health Inc. reported significant financial growth for the first half of 2025, with a total revenue increase of 217.5% compared to the same period in 2024, highlighting the company's strong performance and growth strategy [8][9]. Financial Highlights for the Three Months Ended June 30, 2025 - Total revenue reached $244.0 million, up 220.7% from $76.1 million in the same period of 2024 [9]. - Operating income improved to $33.7 million from $5.3 million year-over-year, marking a $28.4 million increase [9]. - Net loss attributable to Nutex Health was $17.7 million, which included non-cash stock-based compensation expense of $78.7 million [9]. - Adjusted EBITDA was $71.6 million, compared to $6.8 million for the same period in 2024 [9]. Financial Highlights for the Six Months Ended June 30, 2025 - Total revenue for the first half of 2025 was $455.8 million, an increase of $312.2 million from $143.5 million in the first half of 2024 [9]. - Net income attributable to Nutex Health was $3.5 million, a turnaround from a net loss of $0.7 million in the same period of 2024 [9]. - EBITDA for the first half of 2025 was $51.1 million, up 227.4% from $15.6 million in the first half of 2024 [9]. - Total visits at the Hospital Division increased by 15.5%, totaling 93,842 visits compared to 81,276 in the same period of 2024 [9]. Share Repurchase Program - The Board of Directors authorized a stock repurchase program of up to $25.0 million to enhance shareholder value and offset dilution from stock compensation obligations [4][5]. - The program allows for opportunistic repurchases based on market conditions and the company's financial status [6][10]. Company Overview - Nutex Health operates a physician-led integrated healthcare delivery system with 24 micro hospitals and outpatient departments across 11 states [1][19]. - The company focuses on innovative healthcare models and population health management through its two divisions: Hospital Division and Population Health Management Division [19][20].

Core Points - A class action securities lawsuit has been filed against Cytokinetics, Incorporated for alleged securities fraud affecting investors between December 27, 2023, and May 6, 2025 [1][2] - The lawsuit claims that Cytokinetics made materially false and misleading statements regarding the New Drug Application (NDA) submission and approval process for aficamten, particularly concerning the expected FDA approval timeline [2] - The company failed to disclose significant risks related to the omission of a Risk Evaluation and Mitigation Strategy (REMS) in its NDA submission, which could delay the regulatory process [2] Case Details - Defendants allegedly misrepresented the timeline for FDA approval, stating it would occur in the second half of 2025 based on a September 26, 2025 PDUFA date [2] - During an earnings call on May 6, 2025, it was revealed that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a REMS, misleading investors about the regulatory timeline [2] - As a result of these misleading statements, investors purchased Cytokinetics' common stock at inflated prices and incurred significant losses when the truth was disclosed [2] Next Steps - Investors who suffered losses in Cytokinetics during the specified timeframe have until November 17, 2025, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3] Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Core Points - A class action securities lawsuit has been filed against Snap Inc. for alleged securities fraud affecting investors between April 29, 2025, and August 5, 2025 [1][2] - The lawsuit claims that Snap misled investors about its advertising revenue growth, which dropped from 9% in Q1 to only 1% in April 2025 [2] - Following the announcement of disappointing financial results on August 5, 2025, Snap's stock price fell from $9.39 to $7.78, a decline of approximately 17.15% in one day [2] Case Details - The complaint alleges that Snap provided overly positive statements while concealing material adverse facts about its advertising revenue growth [2] - Snap attributed the slowdown in advertising revenue growth to issues with its ad platform, the timing of Ramadan, and minor changes [2] - Investors affected by the decline in stock price have until October 20, 2025, to request to be appointed as lead plaintiff in the lawsuit [3] Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

LFMD investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) defendants materially overstated LifeMD's competitive position; (2) defendants were reckless in raising LifeMD's 2025 guidance, considering that they had not properly accounted for rising customer acquisition costs in LifeMD's RexMD segment, as well as for customer acquisition cost ...